Author

Annie Guerin

Observed institution: Concordia University

ORCID: 0000-0002-9333-0812

Observed ORCID: 0000-0002-9333-0812

OpenAlex ID: A5059569387

Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study

2023 · Mazyar Shadman, Beenish S. Manzoor, et al. · Clinical Lymphoma Myeloma & Leukemia · 17

Treatment Effectiveness of Venetoclax‐Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real‐World Study

2024 · Nilanjan Ghosh, Toby A. Eyre, et al. · American Journal of Hematology · 10

Patient-reported time toxicity with bispecific antibody therapies in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma

2026 · Ajay Major, Esprit Ma, et al. · The Oncologist · 2

Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL: An International Real-World Study

2024 · Nicole Lamanna, Jennifer R. Brown, et al. · Blood · 2

Treatment Patterns and Clinical Outcomes of Patients With Systemic Light Chain Amyloidosis in the United States: Evidence From Real-World Clinical Practice

2025 · Sophia S. Li, Anita D'Souza, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

Impact of Adverse Events on Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs) - Early Results of the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study

2024 · Kelly Schoenbeck, Joan Clements, et al. · Blood · 1

Fixed-treatment duration venetoclax following covalent BTKi progression in chronic lymphocytic leukemia

2026 · Isabelle Fleury, Brian T. Hill, et al. · Blood Neoplasia

Evaluation of ventoclax initiation prophylaxis and monitoring outcomes at each dose level and time point in patients with chronic lymphocytic leukemia: A real-world experience

2025 · Christopher Jensen, Mazyar Shadman, et al. · Blood

POSTER: CML-1030 Quality of Life and Work Impacts Among Caregivers of Patients With Chronic Myeloid Leukemia: A Caregiver Survey in the US

2025 · Kathryn Flynn, Joan Clements, et al. · Clinical Lymphoma Myeloma & Leukemia

CML-1030: Quality of Life and Work Impacts Among Caregivers of Patients With Chronic Myeloid Leukemia: A Caregiver Survey in the US

2025 · Kathryn Flynn, Joan Clements, et al. · Clinical Lymphoma Myeloma & Leukemia

CLL-495 Treatment Characteristics and Outcomes of Patients With Chronic/Small Lymphocytic Leukemia (CLL) Treated With Venetoclax and Bruton Tyrosine Kinase Inhibitor (BTKi) Combination Therapies

2024 · Hande H. Tuncer, Nilanjan Ghosh, et al. · Clinical Lymphoma Myeloma & Leukemia

CML-205 Non-Optimal Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Tyrosine Kinase Inhibitors (TKI) in the United States: A Claims Data Analysis

2024 · Vamsi Kota, David Wei, et al. · Clinical Lymphoma Myeloma & Leukemia

Treatment Characteristics and Outcomes of Patients With Chronic/Small Lymphocytic Leukemia (CLL) Treated With Venetoclax and Bruton Tyrosine Kinase Inhibitor (BTKi) Combination Therapies

2024 · Hande H. Tuncer, Nilanjan Ghosh, et al. · Clinical Lymphoma Myeloma & Leukemia

Works count: 13

Citation count: 33

H-index: 2

I10-index: 2